XMAB6755

XMAB6755 is an investigational bispecific antibody engineered with Xencor's XmAb Fc Domain technologies, used to target autoimmune diseases. The drug incorporates either the Xtend Fc Domain for prolonged half-life, a Cytotoxic Fc Domain, or both, enabling potent immune modulation. The bispecific nature of XMAB6755 is designed to selectively modulate immune responses, potentially by co-engaging targets relevant to autoimmune activity. It is a preclinical or early clinical-stage candidate developed and owned by Xencor for the potential treatment of autoimmune disorders. Further mechanistic details or specific target information are not yet publicly disclosed in the available data[1][3].